Inclusion body myositis.

Rabi Tawil, Robert C Griggs
Author Information
  1. Rabi Tawil: Department of Neurology, University of Rochester, Rochester, New York 14642, USA. Rabi_Tawil@urmc.rochester.edu

Abstract

Inclusion body myositis (IBM) is an inflammatory myopathy with distinctive clinicopathologic features. The etiology of IBM remains elusive. The immune-mediated basis for this disease has been challenged by evidence implicating a number of divergent etiologic factors. These factors include mitochondrial deletions, nitric oxide induced oxidative stress, myonuclear breakdown, and abnormal accumulation within muscle fibers of brain-specific Alzheimer type proteins. The treatment of IBM with conventional immunosuppressive agents has been disappointing. Therapeutic approaches currently under study or consideration are beta-interferon and synthetic anabolic hormones.

MeSH Term

Female
Humans
Immune System
Immunosuppressive Agents
Male
Middle Aged
Myositis, Inclusion Body
Sex Factors
Treatment Outcome

Chemicals

Immunosuppressive Agents

Word Cloud

Created with Highcharts 10.0.0IBMInclusionbodymyositisfactorsinflammatorymyopathydistinctiveclinicopathologicfeaturesetiologyremainselusiveimmune-mediatedbasisdiseasechallengedevidenceimplicatingnumberdivergentetiologicincludemitochondrialdeletionsnitricoxideinducedoxidativestressmyonuclearbreakdownabnormalaccumulationwithinmusclefibersbrain-specificAlzheimertypeproteinstreatmentconventionalimmunosuppressiveagentsdisappointingTherapeuticapproachescurrentlystudyconsiderationbeta-interferonsyntheticanabolichormones

Similar Articles

Cited By